These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17043121)

  • 1. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates.
    Wootton M; MacGowan AP; Walsh TR
    Antimicrob Agents Chemother; 2006 Dec; 50(12):4195-7. PubMed ID: 17043121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Akins RL; Rybak MJ
    Antimicrob Agents Chemother; 2001 Feb; 45(2):454-9. PubMed ID: 11158740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA.
    Yusof A; Engelhardt A; Karlsson A; Bylund L; Vidh P; Mills K; Wootton M; Walsh TR
    J Clin Microbiol; 2008 Sep; 46(9):3042-7. PubMed ID: 18596146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Fernandez J; Abbanat D; Shang W; He W; Amsler K; Hastings J; Queenan AM; Melton JL; Barron AM; Flamm RK; Lynch AS
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1476-84. PubMed ID: 22232278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model.
    Akins RL; Rybak MJ
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1925-9. PubMed ID: 10858356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activities of LY333328 and vancomycin administered alone or in combination with gentamicin against three strains of vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacodynamic infection model.
    Aeschlimann JR; Allen GP; Hershberger E; Rybak MJ
    Antimicrob Agents Chemother; 2000 Nov; 44(11):2991-8. PubMed ID: 11036011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
    Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
    Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-center blinded study on the efficiency of phenotypic screening methods to detect glycopeptide intermediately susceptible Staphylococcus aureus (GISA) and heterogeneous GISA (h-GISA).
    Voss A; Mouton JW; van Elzakker EP; Hendrix RG; Goessens W; Kluytmans JA; Krabbe PF; de Neeling HJ; Sloos JH; Oztoprak N; Howe RA; Walsh TR
    Ann Clin Microbiol Antimicrob; 2007 Sep; 6():9. PubMed ID: 17892555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin.
    Sakoulas G; Alder J; Thauvin-Eliopoulos C; Moellering RC; Eliopoulos GM
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1581-5. PubMed ID: 16569891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 1 year surveillance study of glycopeptide-intermediate Staphylococcus aureus strains in a French hospital.
    Garnier F; Chainier D; Walsh T; Karlsson A; Bolmström A; Grelaud C; Mounier M; Denis F; Ploy MC
    J Antimicrob Chemother; 2006 Jan; 57(1):146-9. PubMed ID: 16286482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
    Leuthner KD; Vidaillac C; Cheung CM; Rybak MJ
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3799-803. PubMed ID: 20585126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative activity of tedizolid and glycopeptide combination therapies for the treatment of Staphylococcus aureus infections: an in vitro and in vivo evaluation against strains with reduced susceptibility to glycopeptides.
    Betts JW; Abdul Momin HF; Phee LM; Wareham DW
    J Med Microbiol; 2018 Feb; 67(2):265-271. PubMed ID: 29300156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effectiveness of common hospital hand disinfectants against methicillin-resistant Staphylococcus aureus, glycopeptide-intermediate S. aureus, and heterogeneous glycopeptide-intermediate S. aureus.
    Wootton M; Walsh TR; Davies EM; Howe RA
    Infect Control Hosp Epidemiol; 2009 Mar; 30(3):226-32. PubMed ID: 19199533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Cha R; Rybak MJ
    Diagn Microbiol Infect Dis; 2003 Nov; 47(3):539-46. PubMed ID: 14596973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
    Marco F; de la Mària CG; Armero Y; Amat E; Soy D; Moreno A; del Río A; Almela M; Mestres CA; Gatell JM; Jiménez de Anta MT; Miró JM;
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2538-43. PubMed ID: 18426900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced expression of the atl autolysin gene and susceptibility to autolysis in clinical heterogeneous glycopeptide-intermediate Staphylococcus aureus (hGISA) and GISA strains.
    Wootton M; Bennett PM; MacGowan AP; Walsh TR
    J Antimicrob Chemother; 2005 Nov; 56(5):944-7. PubMed ID: 16157619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of passage-selected vancomycin-resistant Staphylococcus aureus strains of diverse parental backgrounds.
    Pfeltz RF; Singh VK; Schmidt JL; Batten MA; Baranyk CS; Nadakavukaren MJ; Jayaswal RK; Wilkinson BJ
    Antimicrob Agents Chemother; 2000 Feb; 44(2):294-303. PubMed ID: 10639353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin.
    Sader HS; Fritsche TR; Jones RN
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2330-6. PubMed ID: 16801409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.
    Holmes RL; Jorgensen JH
    Antimicrob Agents Chemother; 2008 Feb; 52(2):757-60. PubMed ID: 18039923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.